Liquidia Corporation (LQDA)
Levi & Korsinsky Announces an Investigation on Behalf of Liquidia Corporation (LQDA) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia challenges regulatory exclusivity for rival's inhaled drug
Liquidia Corp has filed a legal challenge to the U.S. Food and Drug Administration's decision to grant three-year exclusivity to United Therapeutics' inhaled drug used to treat lung disorders, it said on Thursday.
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.
LQDA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Liquidia Corporation Investment
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
LQDA Investors Invited To Participate In Liquidia Corporation Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
These Analysts Cut Their Forecasts On Liquidia
Liquidia Corporation LQDA, on Monday, announced that the Food and Drug Administration (FDA) granted tentative approval of YUTREPIA.
Levi & Korsinsky Reminds Liquidia Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - LQDA
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia, Shake Shack And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the S&P 500 futures gaining around 0.1% on Monday.
US FDA grants tentative approval to Liquidia's inhaled blood pressure drug
The U.S. Food and Drug Administration has granted tentative approval to Liquidia Corp's drug to treat high blood pressure in the lungs, and for patients with a type of lung disorder, the company said on Monday.
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.36 per share a year ago.
Liquidia: Attractive Entry Point After Undeserved SCOTUS Appeal Reaction
The recent UTHR appeal to SCOUTS and the request for a LQDA answer caused an undeserved stock price drop. Interesting entry point as FDA potential approval remains imminent as more than 6 months passed since PDFUA date was delayed. The District Court ruling on patent 327 strengthens Liquidia's position against United's legal actions, as expected in our previous analysis.
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Liquidia stock retook its 50-day line on a U.S. judge's ruling on a patent dispute with United Therapeutics.
